News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2025

26 February, 2025 Year-End Report January-December 2024 News English Regulatory MAR Report Interim Yearend IR Optional
25 February, 2025 Egetis Therapeutics to Host Virtual KOL Event to Discuss MCT8 Deficiency and Emcitate® (tiratricol) on March 4, 2025 News Corporate Information Other Corporate Information English IR Optional
21 February, 2025 Invitation to Presentation of Egetis’ Fourth Quarter and Year-End 2024 Report on February 26, 2025 News Corporate Information Other Corporate Information English IR Optional
20 February, 2025 Egetis Therapeutics to Feature MCT8 Deficiency on Behind the Mystery Airing on Lifetime in Honor of Rare Disease Day News Corporate Information Other Corporate Information English IR Optional
13 February, 2025 European Commission approves Egetis’ Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional

2024

30 December, 2024 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
18 December, 2024 Egetis highlights the positive CHMP opinion for Emcitate®, recent major milestones, and gives a corporate update at Investor Day in Stockholm today News Corporate Information Other Corporate Information English IR Optional
16 December, 2024 Issuance and repurchase of class C shares for incentive programs News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
12 December, 2024 Egetis receives positive CHMP opinion for Emcitate® (tiratricol) for the treatment of MCT8 deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
4 December, 2024 Egetis has decided to explore RTH-beta as the next indication for tiratricol (Emcitate®) News Corporate Information Other Corporate Information English IR Optional
25 November, 2024 Save the Date: Egetis to host Investor Day on December 18, 2024 News Corporate Information Other Corporate Information English IR Optional
8 November, 2024 Interim report Q3 2024 News English Regulatory MAR Report Interim Q3 IR Optional
5 November, 2024 Invitation to Presentation of Egetis’ Third Quarter 2024 Report News Corporate Information Presentation English IR Optional
31 October, 2024 Egetis’ Nomination Committee for the 2025 Annual General Meeting News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
31 October, 2024 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
28 October, 2024 Egetis Therapeutics publishes prospectus for admission to trading of shares on Nasdaq Stockholm News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional
25 October, 2024 Bulletin from Egetis Therapeutics’ Extraordinary General Meeting 2024 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
22 October, 2024 Egetis participates at medical conferences to increase disease awareness about MCT8 deficiency News Corporate Information Other Corporate Information English IR Optional
4 October, 2024 Change in the Board of Directors of Egetis Therapeutics News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
30 September, 2024 NOTICE OF EXTRAORDINARY GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
30 September, 2024 Egetis Therapeutics has successfully carried out directed share issuances amounting to SEK 300 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
30 September, 2024 Egetis Therapeutics announces the intention to carry out directed share issuances of approximately SEK 300 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
19 September, 2024 Egetis submits a patent application to the United States Patent and Trademark Office for “Processes of Preparation” of tiratricol News Corporate Information Other Corporate Information English IR Optional
6 September, 2024 Egetis highlights seven abstracts related to MCT8 deficiency, and two abstracts related to tiratricol and RTH-beta, published ahead of the Annual Meeting of the European Thyroid Association News Corporate Information Other Corporate Information English IR Optional
28 August, 2024 New post-hoc analysis reports effects of tiratricol on patient-centered outcome measures in patients with MCT8 deficiency News Corporate Information Other Corporate Information English IR Optional
Next

Calendar and upcoming reports

April 2, 2025
Van Lanschot Kempen Life Sciences Conference (Amsterdam)

April 30, 2025
Interim Report Q1 2025 (7:00am CEST)

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]